Q: Good evening 5i Team,
Can you please give me your current assessment of Profound Medical?
I've held this stock for about five years. It peaked in 2021 at just over $35, and with the recent drop (due to yet another financing), it's down to about $10.66. I've listened to each earnings call, and it's been the same message for years now that widespread adoption of their non-surgical MRI guided prostate cancer/BPH treatment is just around the corner.
Their "First-time CPT code reimbursement for TULSA" is to be effective January 1, 2025, and they recently partnered with Siemens in a co-sales/marketing deal.
Is more patience (along with patients) warranted here, or is it more likely time to move on? Thanks, Brad
Can you please give me your current assessment of Profound Medical?
I've held this stock for about five years. It peaked in 2021 at just over $35, and with the recent drop (due to yet another financing), it's down to about $10.66. I've listened to each earnings call, and it's been the same message for years now that widespread adoption of their non-surgical MRI guided prostate cancer/BPH treatment is just around the corner.
Their "First-time CPT code reimbursement for TULSA" is to be effective January 1, 2025, and they recently partnered with Siemens in a co-sales/marketing deal.
Is more patience (along with patients) warranted here, or is it more likely time to move on? Thanks, Brad
5i Research Answer:
We've always seen PRN as a company with plenty of potential. It is very small, but growth has...